EQRx Seeks To Establish A More Competitive Market For Oncology Drugs In The U.S.

In 2017, every new cancer drug approved in the U.S. had a launch price over $100,000 . And since then, for drugs with these initial prices, price hikes well above inflation have been commonplace. Moreover, the pricing of these drugs doesn’t correlate to comparative clinical effectiveness, changes in market size, or even the entrance of competitors into various sub-classes of oncology therapeutics. By definition, oligopolistic pricing isn’t competitive.

Read the source article at forbes.com
2022-02-07 00:00:00